EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High performance of the DNA methylation‐based WID‐qEC test for detecting uterine cancers independent of sampling modalities

Ojone Illah iD, Malcolm Scott iD, Elisa Redl iD, James E Barrett iD, Lena Schreiberhuber iD, Chiara Herzog iD, Charlotte D Vavourakis iD, Allison Jones, Iona Evans, Dan Reisel, Dhivya Chandrasekaran, Kostas Doufekas und 7 weitere

International Journal of Cancer · 2024-09 · 155 (5) · 800-806

DOI: 10.1002/ijc.35000 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 13.05.2024. Verfasst von Ojone Illah und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK. Hauptthemen laut MEDLINE: DNA Methylation, Endometrial Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H2020 European Research Council, The Eve Appeal, Land Tirol.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endometrial cancer (EC) is the most prevalent gynaecological cancer in high‐income countries and its incidence is continuing to rise sharply. Simple and objective tools to reliably detect women with EC are urgently needed. We recently developed and validated the DNA methylation (DNAme)‐based women's cancer risk identification—quantitative polymerase chain reaction test for endometrial cancer (WID‐qEC) test that could address this need. Here, we demonstrate that the stability of the WID‐qEC test remains consistent regardless of: (i) the cervicovaginal collection device and sample media used (Cervex brush and PreservCyt or FLOQSwab and eNAT), (ii) the collector of the specimen (gynaecologist‐ or patient‐based), and (iii) the precise sampling site (cervical, cervicovaginal and vaginal). Furthermore, we demonstrate sample stability in eNAT medium for 7 days at room temperature, greatly facilitating the implementation of the test into diagnostic laboratory workflows. When applying FLOQSwabs (Copan) in combination with the eNAT (Copan) sample collection media, the sensitivity and specificity of the WID‐qEC test to detect uterine (i.e., endometrial and cervical) cancers in gynaecologist‐taken samples was 92.9% (95% confidence interval [CI] = 75.0%–98.8%) and 98.6% (95% CI = 91.7%–99.9%), respectively, whilst the sensitivity and specificity in patient collected self‐samples was 75.0% (95% CI = 47.4%–91.7%) and 100.0% (95% CI = 93.9%–100.0%), respectively. Taken together these data confirm the robustness and clinical potential of the WID‐qEC test.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationEndometrial NeoplasmsHumansFemaleSpecimen HandlingMiddle AgedSensitivity and SpecificityUterine NeoplasmsAgedEarly Detection of CancerAdultBiomarkers, Tumor

Stichwörter der Autor:innen

DNA methylationcollection modalitiesearly detectionendometrial cancer

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Women's Cancer, UCL EGA Institute for Women's Health, University College London, London, UK.
  • European Translational Oncology Prevention and Screening (EUTOPS) Institute, Universität Innsbruck, Hall in Tirol, Austria.
  • Department of Gynaecological Oncology, University College London Hospital, London, UK.
  • Department of Pathology, University College London Hospital, London, UK.
  • Department of Gynecology and Obstetrics, General Hospital Hall, Tirol Kliniken, Hall in Tirol, Austria.
  • Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.

ORCID-Profile: Ojone Illah, Malcolm Scott, Elisa Redl, James E Barrett, Lena Schreiberhuber, Chiara Herzog, Charlotte D Vavourakis, Radha Graham, Martin Widschwendter

Förderung

  • H2020 European Research Council
  • The Eve Appeal
  • Land Tirol

Zitieren

APA

Illah, O., Scott, M., Redl, E., Barrett, J. E., Schreiberhuber, L., Herzog, C., Vavourakis, C. D., Jones, A., Evans, I., Reisel, D., Chandrasekaran, D., Doufekas, K., Graham, R., Kotsopoulos, I. C., MacDonald, N., Arora, R., Olaitan, A., Rosenthal, A., & Widschwendter, M. (2024). High performance of the DNA methylation‐based WID‐qEC test for detecting uterine cancers independent of sampling modalities. International Journal of Cancer, 155(5), 800-806. https://doi.org/10.1002/ijc.35000

Vancouver

Illah O, Scott M, Redl E, Barrett JE, Schreiberhuber L, Herzog C, et al. High performance of the DNA methylation‐based WID‐qEC test for detecting uterine cancers independent of sampling modalities. International Journal of Cancer. 2024;155(5):800-806. doi:10.1002/ijc.35000

BibTeX
@article{Illah2024,
  author = {Illah, Ojone and Scott, Malcolm and Redl, Elisa and Barrett, James E and Schreiberhuber, Lena and Herzog, Chiara and Vavourakis, Charlotte D and Jones, Allison and Evans, Iona and Reisel, Dan and Chandrasekaran, Dhivya and Doufekas, Kostas and Graham, Radha and Kotsopoulos, Ioannis C and MacDonald, Nicola and Arora, Rupali and Olaitan, Adeola and Rosenthal, Adam and Widschwendter, Martin},
  title = {High performance of the DNA methylation‐based WID‐qEC test for detecting uterine cancers independent of sampling modalities},
  journal = {International Journal of Cancer},
  year = {2024},
  volume = {155},
  number = {5},
  pages = {800--806},
  doi = {10.1002/ijc.35000}
}
Kostenlos starten →